STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) on behalf of the Company’s investors.
The investigation seeks to determine whether Seres’s board of directors (the “Board”) has violated its fiduciary duty by instituting measures intended to interfere with the ability of Seres’ stockholders to hold the Board accountable for Seres’ recent financial and stock price performance.
Seres stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing ac@abbottlawyer.com or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.
CONTACT:
Abbott Cooper PLLC
Abbott Cooper
(475) 333-0674
www.abbottlawyer.com
Attorney advertising. Prior results do not guarantee a similar outcome.
Global cybersecurity provider deepens sustainability commitment, aiming to secure a better future for the environment.SEATTLE,…
Following the positive progress announced to the market on the Uprated Connection Agreement and the…
Fingerprint Cards AB (FPC) will host a telephone conference and webcast presentation of its first…
Orrön Energy AB (“Orrön Energy”) will publish its financial report for the first quarter 2025…
Q1 2025 FOR SIILI: Siili continued AI strategy implementation and actions for profitability improvements, revenue…
Image by Andrew Jovic DÜSSELDORF, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- Independent art collector…
This website uses cookies.